Hsu, Yu-ChenYu-ChenHsuCHIEN-HUNG CHENHUI-FU HUANGLee, Ying-TeYing-TeLeeWu, Meng-ChuanMeng-ChuanWuSu, Chien-WenChien-WenSuChou, Huei-ChiHuei-ChiChouWang, Li-FangLi-FangWangLee, Hsuan-ShuHsuan-ShuLeeSHU-WHA LINPING-NING HSUYAO-MING WUSheu, Jin-ChuanJin-ChuanSheuMENG-TZU WENG2023-07-182023-07-182023-07-0100411337https://scholars.lib.ntu.edu.tw/handle/123456789/633853Liver transplantation (LT) is the treatment of choice for patients with hepatocellular carcinoma (HCC). Recurrence of HCC after LT occurs in 10% to 20% of cases. Preclinical studies to evaluate immune checkpoint inhibitors in conjunction with immunosuppressant treatment in transplant recipients have been lacking. Here, we evaluated the efficacy, safety, and mechanism of programmed cell death-1 (PD1) blockade under tacrolimus treatment in transplant recipients.en[SDGs]SDG3journal article10.1097/TP.0000000000004425363804502-s2.0-85163537475